Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

6(75%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

25%

Ph not_applicable

13%

Ph phase_4

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

2(50.0%)

Phase 4Post-market surveillance

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Completed(1)

Detailed Status

Recruiting5

Active, not recruiting1

Completed1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 22 (50.0%)

Phase 41 (25.0%)

N/A1 (25.0%)

Trials by Status

recruiting563%

active_not_recruiting113%

completed113%

not_yet_recruiting113%

Recent Activity

6 active trials

Showing 5 of 8

recruitingphase_2

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

NCT06526299

recruiting

PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)

NCT07089550

recruitingnot_applicable

PSMA PET for Surveillance After Focal Therapy

NCT07115914

recruitingphase_2

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

NCT07150715

recruitingphase_4

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

NCT05919329

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06526299Phase 2

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Recruiting

NCT07089550

PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)

Recruiting

NCT07115914Not Applicable

PSMA PET for Surveillance After Focal Therapy

Recruiting

NCT07150715Phase 2

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

Recruiting

NCT05919329Phase 4

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Recruiting

NCT07052877

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

Not Yet Recruiting

NCT06919159

Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer

Completed

NCT02899312

PSMA PET/CT for Assessment of Recurrent Prostate Cancer